QNCX vs. ATRA, VSTM, VTGN, AGEN, OPT, ATHA, VXRT, TVGN, CLLS, and CRDF
Should you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Atara Biotherapeutics (ATRA), Verastem (VSTM), Vistagen Therapeutics (VTGN), Agenus (AGEN), Opthea (OPT), Athira Pharma (ATHA), Vaxart (VXRT), Tevogen Bio (TVGN), Cellectis (CLLS), and Cardiff Oncology (CRDF). These companies are all part of the "medical" sector.
Quince Therapeutics (NASDAQ:QNCX) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations.
Quince Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -671.70%. Atara Biotherapeutics' return on equity of 0.00% beat Quince Therapeutics' return on equity.
30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 16.8% of Quince Therapeutics shares are owned by insiders. Comparatively, 3.7% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Quince Therapeutics has higher earnings, but lower revenue than Atara Biotherapeutics. Quince Therapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Atara Biotherapeutics has a consensus price target of $355.50, indicating a potential upside of 3,395.58%. Given Atara Biotherapeutics' higher probable upside, analysts plainly believe Atara Biotherapeutics is more favorable than Quince Therapeutics.
Atara Biotherapeutics received 429 more outperform votes than Quince Therapeutics when rated by MarketBeat users.
In the previous week, Quince Therapeutics and Quince Therapeutics both had 2 articles in the media. Quince Therapeutics' average media sentiment score of 0.94 beat Atara Biotherapeutics' score of 0.76 indicating that Quince Therapeutics is being referred to more favorably in the media.
Quince Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.
Summary
Quince Therapeutics beats Atara Biotherapeutics on 7 of the 13 factors compared between the two stocks.
Get Quince Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quince Therapeutics Competitors List
Related Companies and Tools
